Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.63 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182434 | 0.95 | DDB1 (0.58) | GID4DDB1CRBNMEN1NPC1 | |
| SCHEMBL4128714 | 0.94 | DDB1 (0.57) | GID4DDB1CRBNMEN1NPC1 | |
| SCHEMBL21286784 | 0.90 | DDB1 (0.67) | GID4DDB1CRBNMEN1NPC1 | |
| SCHEMBL318046 | 0.83 | GID4 (0.43) | GID4DDB1CRBNMEN1KMT2A | |
| SCHEMBL16937274 | 0.82 | DDB1 (0.52) | GID4DDB1CRBNMEN1NPC1 | |
| SCHEMBL11194330 | 0.81 | DDB1 (0.56) | GID4DDB1CRBNMEN1NPC1 | |
| SCHEMBL11637205 | 0.80 | DDB1 (0.55) | DDB1CRBNMEN1NPC1KMT2A | |
| SCHEMBL11534052 | 0.80 | SMN1; SMN2 (0.46) | GID4DDB1CRBNMEN1KMT2A | |
| SCHEMBL12852999 | 0.79 | GID4 (0.68) | GID4DDB1CRBNMEN1NPC1 | |
| SCHEMBL15012600 | 0.79 | GID4 (0.61) | GID4DDB1CRBNMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103328451-B | Compounds for the reduction of beta-amyloid production | BRISTOL MYERS SQUIBB CO | 2015-06-10 | — | — | CN | disclosed |
| CN-103328451-A | Compounds for the reduction of beta-amyloid production | BRISTOL MYERS SQUIBB CO | 2013-09-25 | — | — | CN | disclosed |
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1853578-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006088716-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2006-08-24 | — | — | WO | disclosed |
| CN-1090184-C | Heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-09-04 | — | — | CN | disclosed |
| EP-0736018-B1 | 4,5-DIARYLOXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-07-05 | — | — | EP | disclosed |
| US-6025375-A | INHIBITORY ACTIVITY ON PLATELET AGGREGATION, VASODILATING ACTIVITY, ANTIHYPERTENSIVE ACTIVITY OR THE LIKE AND ARE PROSTAGLANDIN I.SUB.2 AGONISTS, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-15 | — | — | US | disclosed |
| CN-1046714-C | Diaryl oxazole derivative and its preparation method, application and pharmaceutical composition | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-11-24 | — | — | CN | disclosed |
| CN-1229795-A | Heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-09-29 | — | — | CN | disclosed |
| CN-1138328-A | Heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-12-18 | — | — | CN | disclosed |
| EP-0736018-A1 | 4,5-DIARYLOXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995017393-A1 | 4,5-DIARYLOXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-29 | — | — | WO | disclosed |
| US-4079141-A | ANALGESICS | AMERICAN HOECHST CORPORATION (US) | 1978-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ESR2, ERLIN1, ESRRG | GID4 1860/4885DDB1 2574/4885CRBN 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.